Background: Children with multimorbid asthma and rhinitis show IgE polysensitiza-
| INTRODUCTION
Allergic diseases are complex and represent multiple phenotypes 1 such as clinically silent IgE sensitization, isolated phenotypes such as only rhinitis, asthma, dermatitis, food allergy and multimorbidities associating several conditions in the same subject.
In children, multimorbidities of allergic diseases share common causal mechanisms that are partly IgE-mediated. 2 IgE sensitization is heterogeneous, and important clinical and immunological differences exist between mono-and polysensitized patients. [3] [4] [5] An important result from the FP7-funded project MeDALL (Mechanisms of the Development of Allergy) was the identification of the multimorbid polysensitized phenotype of allergic diseases in children, characterized by children with asthma presenting both allergic polysensitization and other allergic diseases, mainly rhinitis. 5 Although polysensitization and allergic-related multimorbidity were known, they had not been associated in a single phenotype. In MeDALL, using hypothesis and data-driven methods, this novel phenotype was shown to be associated with some important features of allergic diseases including a low probability of remission of IgE sensitization and symptoms, [6] [7] [8] elevated levels of total and specific IgE, 9 high levels of blood eosinophils and a high rate of allergy in family history. This newly described phenotype is also associated with the severity of asthma, [10] [11] [12] [13] rhinitis, [11] [12] [13] atopic dermatitis 14 or food allergy. 15 However, this phenotype needs to be confirmed also in adolescents and adults, to understand whether these associations are transient or persistent along the life course. In a previous analysis in adults from the Epidemiological study of the Genetics and Environment of Asthma, bronchial hyperresponsiveness and atopy-EGEA study, first evidence was provided that polysensitization is associated with multimorbid asthma and rhinitis. 16 However, the analysis was limited by the use of allergen extracts which represent mixtures of source-specific genuine allergen molecules and crossreactive allergens so that a true discrimination of co-and cross-sensitization could not be made 17, 18 and by the fact that only a limited number of allergen extracts could be tested by skin prick testing.
Until recently, the IgE sensitization profiling in allergic multimorbidity has been based on a limited number of allergens. Currently, the allergen micro-array technology makes it possible to measure allergen-specific IgE antibody responses to a large number of allergen molecules. In MeDALL, the ImmunoCAP ISAC chip technology 19, 20 was refined to increase its sensitivity and to incorporate new allergens. 20 The resulting MeDALL-chip has been validated and tested in birth cohorts and allows measuring IgE responses to more than 170 allergen components with a sensitivity similar to that of the traditional ImmunoCAP as validated using the major birch pollen allergen Bet v 1-specific IgE.
21-23
The present cross-sectional study investigates whether the multi- (Table S1 ). The measurement of allergen-specific IgE was performed as described. 6, 21 Results are given in ISU. According to previous studies, the positivity of each allergen-specific IgE was defined with a threshold of 0.3 ISU IgE. 6, 21, 22 As previously shown, the agreement between SPT and allergen-specific IgE in EGEA was strong (Cohen Kappa coefficient ≥0.65), with slightly higher prevalences using the MeDALL-chip (except for ragweed) (Table S2) . 28 In BAMSE, agreement for allergen-specific IgE between ImmunoCAP and the MeDALL-chip components was high (Cohen Kappa coefficient ≥0.75) for the most prevalent allergens (timothy grass, birch and cat) and moderate for the less prevalent allergens (house dust mite, horse and mugwort), as expected given the link between the kappa and the prevalence (Table S3) .
Within each study, respiratory allergenic molecules recognized by ≥3% of subjects were considered to address the sensitization profiles of asthma and rhinitis phenotypes (Table S1 ).
| Biases
In both studies, allergen-specific IgE was measured in a subset of samples (for cost issues), randomly selected among the BAMSE samples and in EGEA among the nonasthma and asthma samples separately. Within each group, the selection process was unrelated to the allergen exposure and the allergen-specific IgE reactivity, minimizing the risk for selection bias (Figures S1 and S2).
| Statistical methods
Demographic results are given in means AE SD or n (%). 3 | RESULTS
| Demographic characteristics of participants
There were 840 adult participants in the French EGEA study (463 with and 377 without asthma) and 786 adolescents of the Swedish BAMSE cohort (Figures S1 and S2). In BAMSE and within the asthma and the nonasthma group in EGEA, participants included in the analysis did not differ to those nonincluded regarding allergyrelated characteristics (Tables S4 and S5 ). In the BAMSE study, included participants had more often asthma than nonincluded ones (22.9% vs. 18.0%, P = .02). The demographic characteristics of the SIROUX ET AL.
| 1449 participants are presented in Table 1 . In EGEA, mean age of asthma onset was higher in the A+RÀ than in the A+R+ (19.4 (AE16.0) vs.
13.7 (AE14.6), P = .002). The frequency of asthma-rhinitis multimorbidity (A+R+) was 44% in EGEA and 14% in BAMSE. Asthma only (A+RÀ) and rhinitis only (AÀR+) were found in 11% and 15% in EGEA and 8% and 24% in BAMSE.
| IgE reactivity to allergen molecules
We identified 39 and 18 allergens recognized by IgE in at least 3% of the EGEA population and the BAMSE population, respectively (Table S1 ). IgE reactivities to olive Ole e 1 and house dust mite Der p 1 were frequent in EGEA (20.4% and 26.4%, respectively) and infrequent in BAMSE (1.2% and 1.3%). IgE reactivity to birch Bet v 1 was frequent in BAMSE. IgE reactivities to animal (cat, dog and horse) and grass pollen allergens were similar in both populations irrespective of age difference between the 2 studies.
| Multimorbidity and polysensitization
The number of subjects with IgE reactivity to at least one allergen and the number of IgE-reactive allergens differed significantly between the asthma-rhinitis phenotypes in both studies. IgE sensitizations to few allergens were observed in the AÀRÀ phenotype whereas the greatest number of IgE-reactive allergens was found in the multimorbid A+R+ phenotype (Table 2, Figure 1A ). The A+RÀ and AÀR+ phenotypes showed IgE reactivity to significantly fewer allergens than the A+R+ phenotype (P < .001). As compared to AÀRÀ subjects, the age-and sex-adjusted ratio of the mean number of IgE sensitizations was significantly higher in A+R+ than in A+RÀ or AÀR+, in both cohorts (Table 2 ). There was a difference between EGEA and BAMSE as the A+RÀ group showed IgE reactivity to significantly more allergens in EGEA than in BAMSE.
In EGEA, the number of allergen molecules associated with specific IgE was significantly higher in childhood-onset asthma than in adult-onset asthma (median were 9.0 and 2.0, respectively, EGEA: Rhinitis ever and nose problems apart from cold in the past 12 months; BAMSE: Symptoms of sneezing, a runny or blocked nose, or itchy, red and watery eyes after exposure to furred pets or pollen (latest 12 months) AND/OR doctor's diagnosis of allergic rhinitis from the age of 12 up to the date of questionnaire 16.
P < .0001) ( Figure 1B and Table 2 ). In both childhood and adultonset asthma, the A+R+ phenotype exhibited IgE reactivity to a higher number of allergens than the A+RÀ (P < .001 in childhoodonset asthma and P = .002 in adult-onset asthma) ( Table 2 ). Among subjects with rhinitis, the number of allergen recognized by IgE was higher among subjects with childhood-onset asthma as compared to adult-onset asthma (P < .0001).
In both studies, the prevalence of subjects with IgE reactivity to at least one allergen and the number of IgE-reactive allergens increased gradually with the number of diseases (asthma and rhinitis and atopic dermatitis) ( 
| Sensitization patterns between asthma and rhinitis phenotypes
The patterns of IgE sensitizations differed between the phenotypes and populations (Figures 2 and 3 ). In the AÀRÀ phenotype, IgE reactivity frequency was below 10% for all allergen components in both cohorts, except for Phl p 1 in BAMSE (Figures 2A and 3A) . In the A+RÀ phenotype, Phl p 1, most of the Der p allergens and Fel d 1 were over 10% in EGEA ( Figure 2B ), whereas only Phl p 1 was over the threshold of 10% in BAMSE ( Figure 3B ). In the AÀR+ phenotype, pollen allergens and Fel d 1 were over 10% in both EGEA and BAMSE ( Figures 2C and 3C ). In BAMSE, Can f 5 was also over the threshold of 10% recognition in the AÀR+ phenotype. In the A+R+ phenotype ( Figures 2D and 3D Table S1 ). Relative change in the mean number of IgE-reactive allergens was calculated with negative binomial model.
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| DISCUSSION
Our study shows that the asthma-rhinitis multimorbid phenotype is associated with strong IgE polysensitization, both in adolescents and in adults. The asthma-rhinitis multimorbid phenotype combined the sensitization pattern of both the asthma-only phenotype and the rhinitis-only phenotype. In addition, the systematic highest risk observed for allergen-specific IgE reactivity in the asthma-rhinitis multimorbid phenotype as compared to the asthma-or rhinitis-only phenotypes indicates that the mechanisms involved in the asthmarhinitis multimorbid phenotype might be partly different or enhanced than those involved in asthma-or rhinitis-only phenotypes. The observation found in 2 different populations with exposure to different allergen sources, the Swedish BAMSE cohort and the French EGEA population, provides evidence for the generalizability of this "extreme" phenotype to any age or allergenic environment.
A major strength of our study is the strategy used, by addressing the research question in 2 populations differing regarding many fea- One limitation, relying on the cross-sectional design of our analyses, is the lack of definite information on the timing of the events and of the successive specific allergens sensitization. This timing of events has been addressed in some birth cohort studies. However, none of these previous studies has used defined allergen molecules but only allergen extracts to detect IgE sensitization. A recent study in the MAS and PASTURE cohorts, which identified different sensitization profiles characterized by allergen specificity, time course and sIgE level, did not identify clear temporal sensitization pattern between 1 and 6 years of age. 31 The clusters were mainly characterized by allergen specificity and strength of the sIgE sensitization. In the Paris cohort, Gabet et al 8 identified as early as 18 months of age 3 sensitization profiles, including a "polysensitized" profile which exhibits the highest risk for multimorbidity at 6 years. In the EGEA study, we examined the impact of age of asthma onset on the sensitization patterns. When the disease started in childhood, the number of sensitizations was greater than when the disease started later for both A+RÀ and A+R+ groups. But, the association between the asthma-rhinitis multimorbidity and allergic polysensitization was observed in both childhood-and adult-onset phenotypes. Another limitation could be that IgE measurements on the chip are performed under conditions of low amounts of allergen immobilized to the solid phase which may be affected by allergen-specific IgG antibodies.
However, the MeDALL allergen chip has been carefully evaluated with respect to sensitivity and was found to be more sensitive for detecting IgE sensitization than allergen extract-based skin prick testing and conventional allergen extract-based serology because significantly more sensitized subjects were detected. 22 Our study is clinically relevant and provides results with a general validity because it examines asthma-rhinitis multimorbidity and polysensitization in depth and confirms the hypothesis raised in the recent paper by Burte et al 16 in the same EGEA cohort using classical IgE tests for 12 aeroallergens sources. It is novel as it uses the most advanced method of IgE measurement that is needed to accurately assess true polysensitization, allowing for the assessment of IgE reactivity to define allergen molecules. Moreover, similar findings were observed in a second cohort which allow the generalizability of the results. For the first time, our study showed that for specific allergens with high IgE recognition frequency in the study populations, the risk of IgE reactivity was the highest in the asthma-rhinitis multimorbid phenotype as compared to the isolated asthma or rhinitis phenotypes. This might suggest that the biological mechanisms involved in the association between IgE sensitization and the AR phenotypes are partly different or enhanced in the AR multimorbidity phenotype.
Moreover, in the EGEA study, we observed that the magnitude of the risk for the AR multimorbidity phenotype was roughly the addition of the risk observed in asthma alone and rhinitis alone phenotypes. This might suggest independent effects of allergen-specific IgE sensitization in asthma and in rhinitis (if the effects were mainly shared, the risk in A+R+ would not be higher than the risk in A+RÀ or AÀR+). Our observations provide hypotheses for novel biological explanations which warrant further investigations.
The major difference across the 2 study populations is related to the allergen exposure. In Sweden, exposure to mites is very low, and low level of IgE reactivity to mite allergens probably explains differences in the total number of allergen recognized between EGEA and T A B L E 3 Associations between the number of IgE-reactive allergens and the number of allergic phenotypes (asthma ever, rhinitis ever and atopic dermatitis ever) Among the 64 respiratory allergen components selected (see Table S1 ).
b
Relative change in the mean number of IgE reactivities was calculated with negative binomial model.
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| 1453 F I G U R E 2 IgE recognition frequencies and intensities to respiratory allergens recognized by >3% of the EGEA samples according to the combined asthma and rhinitis phenotypes in EGEA with: A, no asthma and no rhinitis (AÀRÀ), B, asthma but no rhinitis (A+RÀ), C, no asthma but rhinitis (AÀR+) and D, asthma and rhinitis (A+R+) F I G U R E 3 IgE recognition frequencies and intensities of respiratory allergens recognized >3% of the BAMSE samples according to the combined asthma and rhinitis phenotypes in BAMSE with: A, no asthma and no rhinitis (AÀRÀ), B, asthma but no rhinitis (A+RÀ), C, no asthma but rhinitis (AÀR+) and D, asthma and rhinitis (A+R+)
BAMSE and the lack of sensitization in A+RÀ patients in Sweden.
Moreover, in Sweden, birch pollen is highly prevalent whereas it is not common in most parts of France. 7, 28 Thus, the prevalence of birch-related IgE is higher in Sweden than in France. Finally, Ole e 1 is the major allergen of olive and it displays strong cross-reactivity
with Fra e 1, a major ash allergen. 32, 33 These 2 species are common in France but not in Sweden, which explains the low prevalence of Ole e 1-specific IgE in BAMSE as compared to EGEA.
If we consider the impact of environmental exposure, the results are similar in both studies and show that allergic multimorbidity is associated with IgE polysensitization in adults (France) and adolescents (Sweden). Moreover, the levels of allergen-specific IgE are associated with the number of coexisting allergic disease phenotypes. Our study extends to adolescents and adults recent findings in childhood studies and therefore indicates that the allergy multimorbid IgE-polysensitized phenotype starts early in life and does not remit over time, but seems to remain persistent across the life course. In addition, we observed that AR multimorbidity is associated with IgE sensitization to significantly more allergen molecules as compared with asthma alone both in childhood-and adult-onset asthma, emphasizing the generalizability of this phenotype. Recent studies in children showed that this phenotype is associated with the severity of asthma and rhinitis, [11] [12] [13] 15 and therefore underline the relevance of this phenotype at the clinical and public health level. By investigating pathways related to asthma severity in children with asthma and rhinitis, Liu et al 12 showed that allergy was associated with asthma severity through several pathways, from allergic inflammation and subsequently through pulmonary physiology or rhinitis severity.
Our study clearly demonstrated different patterns of sensitization according to the asthma and rhinitis phenotypes, with no or few sensitizations in the AÀRÀ group, with no or predominant sensitization to indoor allergens in A+RÀ, predominant pollen allergens in AÀR+ and frequent IgE sensitization to both pollen and indoor allergens in A+R+. Differences in the A+RÀ sensitization patterns between EGEA and BAMSE might partly be explained by differences in allergenic environment, in particular the infrequent sensitization to house dust mite allergens in Sweden, and differences in the asthma phenotypes considered (eg EGEA also includes adult-onset asthma, which might have different IgE sensitization pattern).
In conclusion, our study provides new insights into the patterns of allergic sensitization across the AR phenotypes in both adolescents and adults. By showing that the allergy multimorbid polysensitized phenotype, previously identified in early life, seems to remain persistent across the life course, our findings advocate for paying a particular attention to this specific phenotype, to identify its underlying mechanisms and risk factors.
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